SGD Pharma has released its latest 2024 Sustainability Report.
SGD Pharma has made significant advancements in its CSR performance outlined in the Report, including:
87/100 Platinum EcoVadis rating, the company’s highest ever score placing it in the top 1 percent of glass manufacturers in the world- Uplifted Science Based Targets initiative (SBTi) targets approved (42 percent reductions by 2030 instead of 35 percent)
- Scores of B and B- respectively in the CDP Climate Change and Water Security programs
- 100 percent of SGD Pharma’s global manufacturing sites in France, China, India and Germany are ISO 14001, ISO 45001 and ISO 50001 certified
- 1000 accident-free days at the Zhanjiang (ZJ), China plant
- 10,000 mangrove trees planted in China in 2024.
For the first time, this year’s Report is voluntarily aligned with the Corporate Sustainability Reporting Directive (CSRD), an achievement made possible through a Double Materiality Assessment (DMA) and gap analysis undertaken in 2024 in collaboration with an independent third party. The DMA investigated SGD Pharma’s entire upstream and downstream value chain to identify key environmental, governance and social as well as financial risks which were then factored into business decisions to mitigate negative impact while leveraging opportunities for sustainable growth.
Investigations into greenhouse gas (GHG) emissions identified potential factors that could decrease emissions further. SGD Pharma will regularly review and update its decarbonisation strategy to assess and manage these risks. As part of the DMA, SGD Pharma also completed a living wage analysis across all its manufacturing sites and offices to ensure fair remuneration for all employees.
Over the last year, SGD Pharma has enhanced its social strategy to maintain the highest levels of employee health, safety and wellbeing across the globe. A new and comprehensive management training curriculum has been designed and is deployed in all our geographies to support company-wide employee development.
Ethics and Integrity are core values at SGD Pharma and the introduction of a global anti-corruption risk mapping for all the SGD Pharma sites helps to identify potential issues which, combined with a solid Ethics and Compliance training program, has contributed to ensuring ethical practice throughout the company. SGD Pharma works to promote sustainable practices within its supply chain.
SGD Pharma has supported the UN Global Compact and aligned its CSR strategy with its ten main principles. In doing so, the company illustrates its dedication to human rights, environmental protection and anti-corruption across all aspects of the business. At SGD Pharma, sustainability comes first and the company shares a collective responsibility towards ensuring an inclusive and environmentally resilient global future.
